Long-term safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase III trials
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.